Cravings-Driven Consumption
A diabetes medication called semaglutide has found new and immensely profitable life as an anti-obesity medication (sold as Ozempic, Mounjaro, and others), dramatically improving the financial outlook of several pharmaceutical companies and providing patients suffering the negative health impacts of obesity an effective means of losing a substantial amount of weight, while also reducing other sorts of cravings.
Since the arrival of this category of drug labeled for this use-case, though, corporate entities from (and investors in) many industries have scrambled to assess how a drug-sparked drop in cravings-driven consumption might impact sales of their products and services, and how better overall health (due to a reduction in obesity and adjacent conditions) might impact the larger healthcare industry.
Keep reading with a 7-day free trial
Subscribe to Brain Lenses to keep reading this post and get 7 days of free access to the full post archives.